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ABSTRACT 
Purpose: The objective of this report is to review the research methods that have been used in the design, 
analysis, and reporting of Phase I dose-escalation studies of high-dose chemotherapy (HDCT) with bone marrow or 
stem cell support and to propose new guidelines for such studies that incorporate merging principles of pharma- 
cology, toxicity assessment, statistical design, and long-term Ibllow-up. 
Methods: We performed a search of original, English-language, peer-reviewed full-length reports of HDCT (with 
or without radiotherapy) and unmanipulated hematopoietie precursor support (antologous bone marrow or stem cells 
or allogeneie bone marrow) in which one or more drug doses were escalated to identify dose-limiting toxieities needed 
for the design of subsequent Phase H trials. We reviewed the design, execution, analysis, and reporting of these trials 
to develop a coherent set of guidelines for the initiation of new HI)CT regimens. The primary elements included in 
our analysis were the technique of dose escalation, the choice and application of toxicity grading scale, and the phar- 
macologic orrelates of dose escalation. We also evaluated the methods employed to define dose-limiting toxicities and 
to select he maximum tolerated ose and the dose recommended for u ther study. We then examined whether subse- 
quent Phase lI trials based on these definitions corroborated the findings from the prior Phase I studies and summa- 
rized the findings from pharmacologic analyses that were reported from a subset of these investigations. 
Results: Thirty-five reports met the criteria for our literature review. Two standard methods of dose escalation 
(fixed increments or modified Fibonaeci increments) were described in detail and were employed in the majority 
(30/35) of the studies. In 5 studies, the details of dose escalation were either not provided or not adequately refer- 
eneed. There was marked heterogeneity among toxicity grading methods; scales used included the National Cancer 
Institute Common Toxicity Criteria (or similar scales such as the United States cooperative group or World Health 
Organization scales) as well as substantially modified versions of those instruments. Wide variations in the methods 
used to identify dose-limiting toxieities were observed. Statistical considerations, applied to the identification of the 
maximum tolerated or Phase II recommended dose, were similarly heterogeneous. Phase II trial designs varied 
from a simple expansion of the Phase I trial to separate, formally conducted studies. Nine Phase I trials featured 
pharmacologic analyses, and these ranged from simple pharmaeokinetie evaluations to more complex analyses of the 
relationship between drug dose and the molecular targets of drug action. 
Conclusions: Phase I clinical trials in the HDCT setting have been designed, analyzed, and reported using het- 
erogeneous methods that limited their application to Phase II and HI investigations. Moreover, correlative pharma- 
cologic analyses have not been routinely undertaken during this critical Phase I stage. We propose guidelines for the 
design of new Phase I studies of HDCT based on 4 essential elements: (1) rational preclinieal and clinical pharma- 
cologic foundation for the regimen a d for the agent selected for dose escalation; (2) incorporation of analytical 
pharmacology in the design and analysis of the regimen under investigation; (3) dear, prospective definitions of the 
dose- or exposure-limiting toxieities that can be distinguished from modality-dependent toxieities; selection of an 
appropriate toxicity grading scale, including an assessment of cumulative, delayed, and long-term effects of HDCT, 
particularly when designing tandem or repetitive cycle regimens; and (4) statistical input into the design, execution, 
analysis, interpretation, and reporting of these studies. 
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BACKGROUND 
General Principles in the Design of High-Dose 
Chemotherapy Regimens 
Basic Principles. Clinical evaluation of novel antineo- 
plastic agents begins with Phase I dose-escalation trials to 
investigate the relationship between dose, schedule, and 
toxicity. If preclinical data suggest a correlation between 
drug exposure and a favorable clinical outcome such as 
objective response or survival, the subsequent Phase II trial 
design usually employs the maximum dose or exposure that 
can be safely administered without exceeding a specified 
rate and level of toxicity. An increasingly precise under- 
standing of the mechanisms ofantitumor activity of existing 
and new drugs has facilitated the design of investigational 
regimens that correlate measures of drug exposure with 
clinical outcomes [1]. 
Studies of new dose-escalation regimens upported by 
autologous or allogeneic hematopoietic precursors (bone 
marrow IBM] or peripheral blood stem cells [PBSC]) are 
also based on the dose-response r lationship of many anti- 
neoplastic agents. The ideal high-dose regimen consists of 
drugs with a high antitumor activity, steep dose-response 
relationships in the preclinical models, and tolerable 
extramedullary toxicities. Additional desirable qualities 
include proven synergy in the combinations chosen for 
study and minimal overlap in their dose-limiting toxicities 
(DLTs). Agents meeting these criteria include cisplatin and 
carboplatin, ifosfamide, doxorubicin, etoposide, and pacli- 
taxel. These agents have activity individually and/or in com- 
bination in germ celt cancers, breast cancer, ovarian cancer, 
and lymphoma, malignancies which have all been studied in 
clinical trials of high-dose chemotherapy (HDCT). Regard- 
less of how well the regimen selected for study meets these 
criteria, the modality itself (BM or stem cell transplantation) 
possesses unavoidable risks that may confound attempts to 
attribute adverse vents precisely to the dose of the agent 
under investigation. This is particularly true in allogeneic 
bone marrow transplantation (BMT), which is complicated 
not only by regimen-related toxicities but also by the spec- 
trum of opportunistic nfections, the multiple organ targets 
of acute and chronic graft-versus-host disease (GVttD), and 
the toxicities and interactions between drugs used to prevent 
and/or treat these complications. In some instances, the 
challenge may be insurmountable; for example, in an early 
report by Petersen et al. [2], 9 patients were treated in a 
Phase I trial of escalating doses of cytosine arabinoside (Ara- 
C) with fixed-dose cyclophosphamide (CTX) and total body 
irradiation (TBI). The regimen-related mortality rate was so 
great that the independent contribution of the Ara-C dose 
could not be determined, and the study was closed without 
meeting its research objectives. 
Toxicity Scales. In 1988, Bearman et al. [3] reported a
new grading system that recognized the need for a distinct 
BMT toxicity scale separate from the Common Toxicity 
Criteria (CTC) developed by the National Cancer Institute 
(NCI). Myelosuppression was not graded on this scale, and 
the maximum nonlethal toxicity was grade III. Grade IV was 
defined as death from any cause, categorized by organ sys- 
tem, or from any toxicity not graded by the new scale. 
The NCI CTC were subsequently revised to include 
modifications for HDCT that addressed the severity and 
duration of cytopenia for each blood cell line (while leaving 
the other organ toxicity grading criteria unmodified). This 
new revision was designed in part to permit assessment of
the potential contribution of both the stem cell product and 
the BM stroma nd associated factors that also influence the 
rate and quality of hematologic and immunologic recovery 
[4]. This scale, which was recommended bythe NCI Cancer 
Therapy Evaluation Program for protocols monitored by 
this program, was never published and did not experience 
broad, consistent use in trials of HDCT. Another modified 
toxicity grading system, similar to that of Bearman et al., 
omits myelosuppression a d assigns grades of toxicity in 
those other organ systems that are most commonly affected 
by HDCT. This scale was also never published or formally 
adopted by the NCI or US cooperative groups. 
Reversible Versus Irreversible Toxicities. One of the 
important shortcomings ofany scale used for high-intensity 
therapy is its failure to distinguish severe but reversible 
adverse ffects from partially or fully irreversible toxici- 
ties. An example of the latter is the peripheral neuropathy 
experienced by most patients receiving high doses of 
paclitaxel; this condition often persists for weeks to 
months, sometimes without fully resolving [5]. The alky- 
lating agent BIS-chloroethyl nitrosourea (BCNU) may 
rarely cause acute lung injury but more frequently causes a
late-onset, chronic fibrosis, the probability of which may 
be related to the area under the curve (AUC) of drug expo- 
sure [6,7]. Other delayed adverse ffects depend on a com- 
plex interaction among the various elements of the regi- 
men and their doses and schedules. For example, 2 distinct 
syndromes of therapy-related leukemia re now recog- 
nized: myeloid leukemias characterized by chromosome 5 
and/or 7 deletions correlate with cumulative xposure to 
alkylating agents and peak in incidence several years fol- 
lowing exposure; and a distinct form of secondary leukemia 
featuring translocations in chromosome 11 at q23 occurs 
with a shorter latency and is predominantly associated 
with exposure to the epipodophyllotoxins [8]. Existing 
methods for correlating these risks with measures of 
chemotherapy exposure (for example, use of molecular 
assays to detect subclinical clonal chromosome damage) 
are under investigation [9]. 
Basis for the Proposed Guidelines. The guidelines 
developed in this review will focus on HDCT regimens 
used for autologous BMT, although some of the reports we 
reviewed as background for these guidelines were based on 
studies of allogeneic BMT, which follow the same principles 
but are more complex in their design and analysis. 
REVIEW OF PUBLISHED PHASE I STUDIES OF HDCT 
WITH STEM CELL SUPPORT 
Methodology 
We prepared a chronologic list of full and original 
reports from the published literature in English-language 
peer-reviewed journals from 1983 through 1998 [10-49]. 
Reports of HDCT had been published over the preceding 
25 years, but they contained small and very heterogeneous 
groups of patients. Furthermore, the earlier investigations 
did not feature HDCT agents of current interest, and tech- 
niques for obtaining the hematopoietic product and for sup- 
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portive care were not comparable to those available begin- 
ning in the 1980s. 
All of the regimens contained a dose escalation of 1 or 
more chemotherapeutic agents and provided BM or PBSC 
support for adult patients with malignant disease (Table 1). 
For each report, we have listed the components of the regi- 
men, the agent(s) escalated, dose ranges, and, wherever 
possible, the dose-escalation scheme, toxicity grading scale, 
definitions of maximum tolerated ose (MTD), recom- 
mended Phase II doses, and dose-limiting toxicities. In 
addition, the source of hematopoietic cells, the total num- 
ber of patients, and the number of patients treated at the 
dose recommended for further study are included. Although 
some of the reports included in our review of Phase I trials 
were titled "Phase I-IF' trials, the Phase I nature of the 
studies predominates, and as shown in the column labeled 
"number at MTD or recommended dose(s)," there was a 
large overlap in the proportion of study patients treated at 
the Phase II dose in studies labeled "Phase I-IF' and those 
without this designation. However, there was insufficient 
information provided in those reports to evaluate whether 
the toxicity profile in the patient cohort at the recom- 
mended dose confirmed the conclusions from the Phase I
compon.ent of the study. 
Dose Escalation 
Among the 35 studies listed, 21 featured fixed incre- 
ments in the dose of 1 or more agents being escalated 
[10,14,15,26-,27,30,32,34-42,45-49]; 5 used a modified 
Fibonaeci scale [17,20,28,43,44]; and 4 featured a limited 
number (2 to 4) of predetermined dose levels [19,22,23,29]. 
In 3 trials, the method of dose escalation was not described 
[21,31,33]. In 2 investigations, the method of dose escala- 
tion was stated to be based on the techniques of a previously 
published report that does not contain any references to 
Phase I dose escalation or toxicities and consists predomi- 
nantly of statistical tables for selecting the numbers of 
patients required for assessment of drug activity in Phase II 
trials [11,13]. The authors of these reports did not describe 
how their dose-escalation schemes were derived from the 
tables in the referenced publication [12]. 
Toxicity Grading 
An even greater degree of variability is evident in the 
choice and application of toxicity grading scales. Three 
reports did not identify the scale used for the assessment of
toxicities [14,19,26]. One early study used a customized sys- 
tem described in the text [10], and 1 referred to a previously 
published report [13]. The largest number of studies (9) 
employed a US cooperative group common toxicity scale or 
the NCI CTC [17,20,22,27,29,33,41,46,49], 1 of which was 
modified for selected organ toxidties [49]. The World Health 
Organization (WHO) scale was used in 7 other trials 
[15,21,31,37,38,40,47], 2 of which were modified for gas- 
trointestinal toxicities [31,47]. Six groups of investigators u ed 
the Bearman scale [22,32,34,35,42,43], and 8 groups 
employed the NCI CTC or a cooperative group scale modi- 
fied for autologous BMT [11,28,30,36,39,43,44,48]. Review 
of the Phase I studies listed in Table 1 revealed that prospec- 
tive definitions of the dose-limiting toxicities and the MTD 
or the dose of the agent o recommend for further evaluation 
were lacking in t3 studies [14,15,17,19-22,27,29,33,38,42,46]. 
The remaining 22 reports contained variably detailed escrip- 
tions of the identification of dose-limiting toxicities and the 
MTD or dose recommended for Phase II trials [10- 
12,23,26,28,30-32,34-37,39-41,43-45,47-49]. The distribu- 
tion of dose-limiting toxicities was not always predictable 
from the known toxicities of the drugs selected for study. The 
organ system most commonly cited as defining dose-limiting 
toxicity (DLT) was the gastrointestinal tract. Hepatic and pul- 
monary toxicities limited dose escalations in a smaller number 
of patients, followed by nephrotoxicity and neurotoxicity. 
Pharmacologic Correlates 
Table 2 provides amore detailed analysis of the 9 studies 
that met the criteria for our Phase I HDCT review and also 
included correlative pharmacologic studies. The stated 
objectives of these analyses varied widely, including correla- 
tions of drug dose with drug concentration i plasma or 
serum [15,17,21,23,26,49-51], effects of variations in organ 
function on the metabolism and clearance of the study drug 
[39], the penetration of the study drug into extravascular 
spaces (cerebrospinal fluid [11] or effusions [26]), establish- 
ment of the extent of drug clearance prior to rein fusion of 
the cryopreserved stem cell product [15,19], and assessment 
of the effects of the study drug on its own active metabolism 
[391 or that of the other agents used in the trial [49]. Alt 
authors either referenced their pharmacoanalytic methods 
or described them in detail. 
Application of Phase I Data to the Design and 
Analysis of Phase II HDCT Trials 
In Table 3, the 16 published reports of formal Phase II 
trials carried out using the recommended dose from a 
Phase I HDCT study are summarized [33,52-68]. We 
found that most authors consistently used the term maxi- 
mum tolerated dose to describe the highest dose associated 
with an acceptable or safe level of toxicity, as detailed in the 
corresponding Phase I study. 
In general, the findings from Phase I trials were corrob- 
orated by the corresponding Phase II trials. In many 
instances, the authors and institutions were the same, sug- 
gesting that factors such as patient selection, techniques of 
supportive care, and evaluation of the data were applied 
consistently. However, data from an important example of 
sequential studies by the same investigators at the same 
institution reveal that these factors are also subject to 
change, typically favoring outcomes in later studies over 
those of earlier studies due to the effect of increased experi- 
ence over time. Thus, in the series of studies published by 
Peters and colleagues, the MTDs of BCNU, cisplatin, and 
CTX were selected from a Phase I study [19] and investi- 
gated in 2 subsequent Phase II trials [55,56]. Using identical 
doses of all 3 agents, the first Phase II trial, published in 
1988, had a 24% mortality rate from multiorgan toxicities 
due to a combination of modality- and regimen-related 
causes. This trial enrolled 21 patients with metastatic breast 
cancer who had not received prior chemotherapy for 
advanced isease [55]. In the subsequent trial, published in 
1993, 85 patients with high-risk primary breast cancer 
received the same regimen following limited exposure to a 
standard CTX/methot rexate /5 - f luorourac i l  adjuvant 
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regimen. The mortality rate in this group of patients was 
12% [56]. Although these data do not come from random- 
ized trials, it is likely that changes in the pattern of patient 
referral and supportive care contributed to the reduction in 
the mortality of therapy. With the substitution of autolo- 
gous peripheral blood stem cell transplantation (aPBSCT) 
for BMT, which is associated with a significant reduction in 
the reconstitution time, and the availability of hematopoietic 
growth factors, which also enhances the rate of hemato- 
poietic recovery, the mortality rate associated with HDCT 
has decreased further to <5% for solid tumors and approxi- 
mately 10% for lymphomas at most institutions. 
CONSIDERATIONS IN THE DESIGN OF FUTURE 
PHASE I HDCT TRIALS 
Selection of Therapeutic Agents 
For many chemotherapeutic agents, a modest increase 
in drug exposure (area under the concentration-time 
curve) can result in a 10-fold increase in the in vitro cyto- 
toxicity, which is the minimal increment in tumor-cell kill 
that may lead to clinical benefit [1]. The steepness of the 
dose-response r lationship and the data available from 
animal models about the therapeutic ndex that predicts 
the relationship between therapeutic efficacy and DLTs 
should be considered in selecting a formula for dose esca- 
lation. Interactions between the drug to be escalated and 
the agents to be used at fixed doses must also be under- 
stood. Every protocol should address the interpretation 
and management of the expected toxicities and should also 
provide a scale and instructions for the assessment of 
unexpected toxicities that take into account heir severity, 
duration, and relation to the therapeutic agent under 
investigation and other agents in the trial. These elements 
are required for the precise definition of the MTD and 
the dose to be recommended for further study after com- 
pletion of the Phase I trial. 
Drug Dose and Modality-Related Considerations 
Probably the most challenging aspect of this element of 
protocol design is the method employed to distinguish drug 
dose- or exposure-related toxicities from adverse vents 
occurring unavoidably in patients undergoing this therapeu- 
tic modality. Neutropenic fever occurs in most patients; 
however, the complications of infection (bacterial, fnngal, 
viral, and opportunistic) or other low-frequency events 
occurring as a consequence of the overall regimen but not 
directly related to the dose of a single component of the 
regimen are the background against which these dose- or 
exposure-related toxicities must be assessed. A thorough 
understanding of the agent's pharmacology and the interac- 
tions at standard oses, supplemented by a familiarity with 
the data from animal studies in which drug exposures are 
often increased to lethal toxicity, will narrow the focus to 
expected DLTs in 1 or a limited number of organ systems. 
In designing the elements of the regimen, the ideal 
approach would superimpose the dose escalation of the 
agent under investigation onto an existing therapeutic 
framework for which there is already sufficient toxicity data 
and for which the expected ose-related toxicities of the new 
agent do not overlap with those that defined the dose and 
schedules used in the existing regimen. In some instances, 
reducing the doses of other agents in the regimen may be 
necessary to more reliably distinguish modality-associated 
toxicities, DLTs of the agents in the backbone regimen, and 
new DLTs of the agent undergoing escalation. The rapid 
emergence of new drugs with novel mechanisms of activity 
has provided investigators with an oppornmity to combine 
agents with relatively nonoverlapping toxicities that still 
meet the criteria for dose escalation to levels requiring 
PBSC support. It is nevertheless e sential that variables uch 
as the irreversible ffects of prior therapy (eg, neuropathy 
and cardiac dysfunction), acquired or genetic alterations in 
the metabolism and clearance of chemotherapeutic agents, 
and the potential for interactions with other drugs and com- 
plications (especially those associated with bacterial, viral, 
and fungal infections) be recognized. The BMT criteria in 
the new NCI -CTC version 2.0 have the potential to 
improve this aspect of protocol design and analysis. 
Pharmacologic Correlates 
Pharmacokinetic and pharmacodynamic analyses have 
not been applied consistently to clinical trial design for 
high-dose regimens. In most cases, Phase I HDCT trials 
have escalated rug dosages beyond the range for which 
pharmacologic data exist. Many agents, such as paclitaxel, 
display dose-dependent pharmacokinetics leading to dispro- 
portionately arge increases in systemic exposure with mod- 
est increases in dose [69]. Moreover, many of the anticancer 
agents and biochemical modulators share the same pathways 
of elimination, leading to significant drug interactions when 
these agents are combined. In addition to disproportionate 
increases in systemic exposure, interpatient variability in 
drug disposition is magnified at higher doses. Both inter- 
and intrapatient pharmacokinetic variability are further 
influenced by the route of administration. For example, the 
pharmacokineties of busulfan are significantly less pre- 
dictable when the drug is given orally compared to the 
intravenous route due to erratic oral absorption [70]. There- 
fore, it is essential that future Phase I HDCT trials include, 
at a minimum, correlative pharmacokinetic investigations of
the agent(s) being escalated. 
As a result of the wide patient-to-patient differences in 
measured rug exposure, efforts are now underway to opti- 
mize high-dose therapy by controlling for the pharmacoki- 
netic variability within individuals. A similar approach as 
led to the standardization f carboplatin dosing based on a 
desired systemic exposure (AUC) rather than body surface 
area. Using either test doses or real-time dosage adjustments 
with feedback, it is now possible to dramatically decrease the 
interindividual variation in exposure to chemotherapeutic 
agents. Although one must first know something about he 
pharmacoldnetics of the drug at tile doses being used, it is 
likely that this "adaptive control" approach will provide 
more precise targeting of drug exposure for both therapeu- 
tic and safety purposes than traditional dose-estimation 
methods uch as the calculation of body surface area [71]. 
Example of Rational Trial Design 
Use of Preclinical and Clinical Data in Trial Design. 
Based on preclinical [72-74] and clinical investigations ofcyclo- 
sporin A (CsA) modulation of paclitaxel [75] and paclitaxel 
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plus carboplatin [76], we recently completed a Phase I study 
of cis-diamminedichloroplatinum (CDDP), CTX, CsA, and 
escalating doses of paclitaxel [77]. 
The dose and schedule of CsA were based in part on the 
results of our prior Phase I trial of escalating doses of infu- 
sional CsA with carboplatin [78], including molecular corre- 
lates of selected oncogene xpression [79,80], and on data 
from other investigators documenting the clinical activity of 
CsA/carboplatin platinum-refractory varian cancer [81]. 
Dose Escalations and Estimation of the MTD and 
DLTs. After 3 patients were treated at each dose level and 
observed for at least 30 days, the subsequent cohort of 
3 patients could be treated at the next dose level of pacli- 
taxel. Basing the paclitaxel dose increments on a modified 
Fibonacci scheme could result in excessive plasma levels of 
this drug in the presence of CsA so we selected a starting 
dose of paclitaxel that was 40% of that which had been 
reported to be effective and safe in treatment with 96-hour 
infusion without peripheral blood progenitor cell support 
[76]. Toxicities were evaluated according to the original 
NCI CTC, but selected organ toxicities were modified to 
avoid using modality toxicities, such as sepsis, to estimate 
the MTD. Special attention was focused on the dose-related 
toxicities expected from paclitaxel in the presence of poten- 
tial additive or even synergistic neurotoxicity from cisplatin 
and CsA. To account for the possibility of a dose-dependent 
delay in hematologic reconstitution due to effects of high- 
dose paclitaxel on the BM stroma, we graded hematologic 
toxicity using the supplementary grading scale. There 
remains a need to better quantify the mucosal toxicities 
(pain, number of days requiring parenteral narcotics or 
nutritional support, extent and depth of ulceration, hemor- 
rhage) associated with all HDCT programs; thus, our evalu- 
ation of the level of mucosal injury was unavoidably subjec- 
tive, based on the judgment of the patient, nurse, and 
physician. Estimation of the MTD based on the number of 
observations ofdefined grade 3 or 4 toxicities in cohorts of 3 
patients (no DLT) or 6 patients (at the levels associated with 
toxicities requiring further accrual to confirm or rule out 
DLTs) was clearly detailed in the protocol. 
In this trial, we found mucositis to be dose-limiting 
using prospectively defined criteria for paclitaxel dose esca- 
lation in combination with fixed doses of CDDP, CTX, and 
CsA. Peripheral neuropathy, also severe in some patients at 
this dose level, was of more variable onset, severity, and 
reversibility. We also performed a series of pharmacologic 
analyses to determine the relationship between paclitaxel 
exposure and the severity of these toxicities. 
Based on the significant interpatient variability in pacli- 
taxel plasma pharmacokinetics determined at the MTD, a 
formal Phase II trial was initiated in which individual pacli- 
taxel exposures were adaptively controlled starting 48 hours 
after initiation of the infusion. Using the adaptive control 
approach, paclitaxel AUCs in patients receiving individually 
adjusted oses were all within approximately 10% of the tar- 
get value. Interestingly, paclitaxel doses required to achieve 
the target AUC ranged from 90 to 225 mg/m 2, without he 
occurrence of DLT. This "tailored" approach to HDCT 
may be of significant value in future trials because of the 
extraordinary interpatient variability in the pharmacokinet- 
ms of most of the drugs employed in the HDCT setting [1]. 
GUIDELINES FOR THE RATIONAL DESIGN OF PHASE I 
HDCT TRIALS 
Based on our analysis of current and prior dose-escalation 
studies of HDCT, we propose a set of guidelines based on 
4 essential elements that should be considered in the design 
of Phase I trials for the study of new dose-escalation regi- 
mens of antineoplastic agents. Although the rationale for 
these recommendations a d our literature review are limited 
to existing knowledge about chemotherapeutic agents, these 
elements could be modified and applied to the design of tri- 
als with novel agents uch as radiolabeled antibodies or 
immunotoxins. Investigators designing new HDCT trials 
should consider the following guidelines. 
Preclinical and Clinical Foundation for the Choice of 
Therapeutic Agents, Dose, and Schedule 
The design of new HDCT regimens generally involves 
the modification of an existing regimen in which the agent 
to be escalated is added to MTDs of 1 or 2 other drugs. To 
avoid excess toxicity and risks, and to optimally observe the 
potential therapeutic nteractions among the agents, it is 
generally advisable to lower the doses of those agents while 
adding and escalating the investigational agent. A firm basis 
in preclinical data supporting the selected combination and 
its use at high doses (a steep dose-response r lationship) 
should provide the rationale for the regimen and the dose 
range of the agent undergoing dose escalation. 
Analytical Pharmacology in the Design of Phase I 
HDCT Trials 
Close collaboration between the pharmacology labora- 
tory and clinical investigators is also essential to the rational 
design of Phase I HDCT trials. Measures of drug exposure, 
such as peak plasma level and area under the concentration- 
time curve, are more likely to predict he toxicity and the 
therapeutic potential of anticancer agents than calculations 
of doses based on weight or body surface area; simplifica- 
tion by moving from dose calculations to fixed doses, par- 
ticularly for agents known not to show a direct relationship 
between body surface area-based osing and drug dear- 
ance, has been proposed and implemented in selected clini- 
cal trials [51]. Because the goal of Phase I HDCT trials is 
to escalate drug doses to the point where new, nonhemato- 
logic DLTs are observed, it is important o determine 
whether DLT is better predicted by the measured rug 
exposure or by the administered dose. In our example, the 
demonstration that the paclitaxel AUC was a better predic- 
tor of toxicity than dose led to refinement of the regimen 
and individual optimization of HDCT for Phase II. More- 
over, pharmacokinetic optimization of HDCT regimens 
may ultimately have a positive impact on treatment out- 
comes. For example, although the cure of childhood acute 
lymphoblastic leukemia (ALL) was one of the first triumphs 
of modern oncology, it was only recently reported that the 
application of pharmacologically guided-- rather than body 
surface area-based--dosing of the standard therapeutic 
agents could result in as much as a 10% increase in the rate 
of cure [82]. This would not have been possible without he 
prior descriptive pharmacokinetic studies of the drugs used 
in the treatment of ALL, demonstrating wide interpatient 
variability. 
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Correlative pharmacologic analyses can also evaluate 
active or toxic drug metabolites, the molecular mechanisms 
of antitumor effects and drug resistance, and interactions 
among drugs, including toxicity or resistance modulators. 
They also provide the data required for adaptive modifica- 
tion of the dose and schedule of the investigational gent. 
Furthermore, some of these molecular studies will ulti- 
mately provide further insight into the mechanisms of 
oncogenesis (relevant to both the primary tumor and to the 
risks of secondary malignancy) and risks of late or cumula- 
tive toxicities. 
The ultimate goal of HDCT is to increase the number 
of patients who can achieve long-term remissions and possi- 
ble cure of their malignancy. Mthough the lack of clinical 
evidence for a steep dose-response r lationship for most 
agents or for improved survival using higher doses of chemo- 
therapy below those requiring BMT/SCT [83-86] have dis- 
couraged many investigators and clinicians in this field, this 
goal remains worthy of pursuit in selected patients. 
Selection of an Appropriate Toxicity Grading Scale 
and Definition of the Dose- and/or Exposure-Limiting 
Toxicities 
Dose-Related Versus Modality-Related Acute Toxicities. 
Modality-related toxicities fall into 2 general categories. (I) 
The obligatory period of pancytopenia can be influenced 
only modestly by alterations in stern cell procedures and 
postinfusion hematopoietic growth factors. Escalation of 
1 of the drugs to DLT is not expected to alter this invariable 
consequence of HDCT, and the duration and degree of 
myelosuppression should generally be excluded from the 
analysis of a drug dose escalation unless the drugs are 
expected to affect the interaction between the stem cell 
product and the marrow microenvironment. (2) The associ- 
ated risks of life-threatening infection and of serious hemor- 
rhage should also be excluded from the DLT definitions of 
the agent undergoing escalation, although the possibility of 
interactions between dose-related toxicities of the investiga- 
tional agent, such as mucositis, and regimen-related risks, 
such as bacterial sepsis, should also be considered in evaluat- 
ing the toxicity spectrum and estimating the MTD [87]. 
Delayed Toxicities. One of the toxicity considerations that 
has been least adequately addressed in the design of Phase I
HDCT trials is the occurrence of cumulative, prolonged, or 
delayed toxicities. Careful assessment of these risks and their 
incorporation into the estimation of MTD would require 
more prolonged patient follow-up and thus slow the pace of 
accrual, of dose escalation, and of study completion. How- 
ever, in contrast o the often repeated cycles of standard- 
dose chemotherapy in patients who are benefiting from 
treatment, HDCT is limited to 1 or 2 cycles, so the observa- 
tion of delayed adverse effects is facilitated. BCNU is an 
example of this rare phenomenon, characterized by late- 
onset oxicities of a single exposure that limit the dose more 
than its acute toxicities. It is not yet clear whether pharma- 
cologic toxicity monitoring can significantly reduce the risk 
of life-threatening pulmonary fibrosis [88]. 
The following suggestions for the design of tandem 
HDCT cycles address the need for better understanding of
the acute and long-term consequences of this therapy. (1) 
Tandem cycles of the same regimen: Patients may begin 
cycle I of a new dose level if the required number of 
patients has safely completed the first cycle of the prior dose 
level, even if toxicity data from cycle 2 are not yet available. 
However, prior to the administration of a second cycle of 
therapy to patients at the higher dose level, all of the sec- 
ond-cycle toxicity data from the lower-dose cohort would 
need to be reviewed so that in the event of DLT, a dose 
adjustment could still be applied to the second cycle for 
patients in the higher-dose cohort. (2) Dose escalation lim- 
ited to cycle 1 and/or omission of the drug undergoing esca- 
lation from the second cycle of therapy: In this approach, 
only the first cycle of high-dose therapy features a dose 
escalation of the study drug, even if the drug under investi- 
gation is to be administered uring the second cycle. The 
drug dose would be constant (and fixed at a known tolerable 
level) in the second cycle, and all of the investigations and 
decisions about dose escalation would be based on data 
obtained from the first cycle of therapy. Dose escalation and 
laboratory correlates would then be based only on data col- 
lected during the first cycle for all cohorts. Data from subse- 
quent cycles, which may be important for the assessment of
cumulative ffects, are exploratory. 
Prospective Assessment of the Late Complications of 
HDCT. The development of secondary malignancies in 
patients who have been successfully treated for their origi- 
nal neoplasm is a consequence of interactions among sev- 
eral factors, including the specific therapeutic agents at the 
doses and schedules administered and other genetic factors 
that are only incompletely understood. Most of the existing 
literature regarding the development of secondary malig- 
nancy, including the specific organ systems at risk, latency, 
genetic markers, and natural history, is derived from retro- 
spective analyses of large patient cohorts who were fol- 
lowed for prolonged periods after successful treatment with 
HDCT [89-93]. As an essential part of evaluating new regi- 
mens, protocols for HDCT should provide methods for the 
prospective analysis of late toxicities. Routine clinical 
methods uch as pulmonary function tests, cardiac imaging 
studies, and laboratory tests of hepatic, renal, and thyroid 
function may reveal early evidence of organ dysfunction 
before clinical manifestations occur and may reveal a higher 
than expected incidence of abnormalities. Screening for sec- 
ond malignancies i  based on routine follow-up examinations 
and established screening methods, such as mammograms 
and possibly thoracic radiographic studies; newer methods 
are under evaluation for detection of myelodysplasias/ 
myeloid leukemias, the earliest evidence of molecular dam- 
age leading to the development of this most devastating 
secondary complication of HDCT. 
A New Toxicity Grading Scale: NCI-CTC Version 2. 
Problems arising in prior studies from the inconsistent use of 
toxicity grading scales are likely to be resolved as the exten- 
sively revised NCI-CTC version 2 is adopted for use in clini- 
cal trials. In this new scale, selected systems are assigned sep- 
arate toxicity grades for patients undergoing BMT (PBSCT). 
However, it remains impossible to devise a system that avoids 
the arbitrary distinction between toxicity grades; further- 
more, identical grades of toxicity in different organ systems 
may have substantially different clinical impacts and implica- 
tions for dose escalation. The arbitrary definition of excessive 
toxicity by its occurrence at a particular grade of severity 
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(eg, grade 3 or 4), without regard for system and attribution, 
should be avoided. It is preferable to select and detail in the 
protocol those systems most likely to reflect he dose-related 
toxicities of the investigational agent. The CTC can then be 
used as a reference for other systems, with a precise descrip- 
tion of how they will be interpreted and used in the dose- 
escalation procedures and overall analysis. Toxicities that are 
to be excluded from consideration i estimation of the 
MTD should also be listed. 
Statistical Design and Analysis in Phase I HDCT 
Trials 
The Statistician in HDCT Trial Design. Statistical 
aspects of the design and analysis of clinical investigations 
should be as rigorous as possible, given the challenges of 
imprecision imposed by experimentation human sub- 
jects. Newer statistical methods are replacing the traditional 
designs and their variations featured in most of the reports 
reviewed earlier, and statisticians working as part of the clin- 
ical trial team have the opportunity to test novel approaches 
to dose escalation and pharmacology. 
Methods for Dose Escalation. Traditional designs for 
patient assignment in Phase I trials involve the treatment of 
a small number of patients (usually 3) at each planned dose 
level and a dose-escalation scheme based on expected rela- 
tionships between drug dose and exposure from published 
preclinieal studies. Modifications of the Fibonacci scheme, 
as described by Gordon and Willson [75], provide for dose 
escalation in successive patient cohorts as long as no DLT 
(usually defined as grade 3 or greater in the original NCI- 
CTC, without further qualification) occurs. As soon as a 
DLT occurs, the possibility that MTD has been exceeded is
tested by the addition of patients at the preceding (lower) 
dose level. The definition of the MTD or Phase II dose is 
generally the level associated with no more than one grade 3 
or greater toxicity among 6 patients in the expanded cohort. 
The presumption that exposure to higher drug levels 
will improve the clinical outcome is often based on preclini- 
cal data and provides the rationale for MTD-seeking Phase 
I trials and for HDCT. Traditionally, Phase I studies have 
sought dose levels that produce moderate toxicity in most 
patients by seeking dose levels that produce DLT in a mod- 
est proportion of patients. The statistical literature typically 
treats a Phase I study in oncology as a calibration problem, 
seeking a dose that produces DLT in a specified fraction of 
the population. The extension of this strategy to the HDCT 
setting hinges on a definition of DLT that excludes modal- 
ity-associated toxicities intrinsic to HDCT regimens either 
as a result of the overall approach (eg, an increased risk of 
life-threatening infection due to an obligatory period of 
neutropenia) or associated with one of the agents that is not 
undergoing dose escalation but for which the dose chosen 
for the combination represents the MTD from a prior 
Phase I trial (eg, mucositis due to radiation or drugs like 
doxorubicin, etoposide, or paclitaxel). 
In the standard-dose tting, a Phase I study design 
seeks to sample the dose-toxicity curve in the vicinity of the 
MTD,  rising quickly from subtherapeutic doses, but 
approaching the MTD cautiously from below. The agents 
used in the high-dose setting will already have established 
activity and toxicity at or near the lowest dose level, making 
accelerated escalations and even the modified Fibonacci 
scheme inappropriate. The cumulative and persistent toxici- 
ties that may be encountered create an even greater need to 
approach the MTD cautiously. Taken together, these con- 
siderations suggest that Phase I trials of HDCT as opposed 
to standard-dose chemotherapy regimens hould use moder- 
ate dose-escalation steps, with relatively more patients 
within a given range of doses. 
The difficulty in separating toxicities associated with 
fixed-dose components of a regimen from those related to 
the dose of the agent being escalated increases the difficulty 
of estimating a dose level with a targeted DLT rate. It 
would seem difficult to put much confidence in an estimate 
of the MTD from a study that could not detect a significant 
association between dose and toxicity. Gordon and Willson, 
for example, advise against using interval estimates of the 
MTD in the absence of a significant regression of toxicity 
on dose [94]. Such a situation can easily arise in standard 
dose-escalation schemes. For example, if a study assigns 
6 patients to each of 3 escalating doses and observes 0, 1, 
and finally 2 DLTs, most standard ose-escalation schemes 
would call the middle dose the MTD, but a logistic regres- 
sion on equally spaced oses would fail to detect asignificant 
dose-toxicity relationship, despite the bias toward positive 
association created by the data-dependent stopping rule, 
because the number of events is too small. Accelerated 
titration designs and continual reassessment methods have 
recently been used to acquire the necessary dose-toxicity 
relationships while minimizing patient exposure to subther- 
apeutic drug doses; safety is also enhanced by allowing 
intra-patient dose escalations upon retreatment. Mthough 
this technique is of limited value in most Phase I HDCT 
trials because of the nonrepetitive nature of the therapy and 
the difficulty distinguishing dose from modality effects, it 
may be applied to selected studies of tandem HDCT cycles, 
as detailed earlier in this review. 
The total number of patients can be increased by 
increasing the number of patients per cohort or the number 
of dose levels spanning a given dose range. The traditional 
dose-escalation schemes consider only 1 dose level at a 
time, typically stopping escalation when 2 DLTs are seen in 
a cohort of 6 patients. The effect of decreasing the size of 
dose increments with these schemes i  to reduce the MTD 
(because DLT occurs at or above the true MTD, so break- 
ing up the intervals increases the chance that DLT will be 
observed at a level closest o the true MTD and that the 
MTD will not be missed or exceeded by the use of large 
dose increments). The use of larger cohorts, which simi- 
larly increases the sample size to enhance the probability of 
identifying the true MTD,  also requires extending the 
dose-escalation decision rules, which must be dependent on 
the spacing of the dose levels relative to the expected ose- 
toxicity curve. This can be evaluated using methods 
described by Storer [95], or by simulation. The operating 
characteristics for a single dose level are simple binomial 
distribution functions. The continual reassessment method 
[96] makes use of all accumulating data, but its develop- 
ment has been oriented more toward rapid dose escalation, 
and it has yet to see wide use. 
The expansion of the cohort at a putative MTD may per- 
mit the observation of additional events. Such an expansion 
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is ethical, as the MTD is often taken as the dose recom- 
mended for Phase II trials, although several authors [97,98] 
suggest that the dose recommended for Phase II investiga- 
tions should be based on analysis of all of the data and not 
solely on the application of a sequential dose-escalation 
scheme. If analysis of accumulated data suggests a Phase II 
dose different from the final dose in the trial, an expanded 
final dose might be used to gain experience at a tentatively 
recommended Phase II dose. 
An alternative means of obtaining additional events is to 
analyze the grade of dose-related toxicities, instead of basing 
the analysis on the presence or absence of the defined DLT. 
The use of all grades of toxicity has been proposed for Phase 
I trials, but usually in the context of accelerated escalation 
from very low doses. Simon and colleagues [97] describe a
method of analysis that attempts to estimate the probabili- 
ties of seeing moderate toxicity and DLT at the various dose 
levels. Regardless of the particular method of analysis, the 
detection of an increase in low-grade toxicities with increas- 
ing dose provides ome reassurance that an MTD based on 
DLTs does in fact reflect dose-related toxicity, as opposed to 
the coincidental occurrence of modality-associated oxicity. 
If the aim of a Phase I study is to identify adose level associ- 
ated with moderate toxicity to DLT, one expects to observe 
moderate toxicities as well as DLTs near the MTD. 
Several strategies can be employed to improve the 
power for detecting, and the precision of estimating, a dose- 
response relationship. A definition of DLTs that excludes 
expected modality-associated oxicities may have a stronger 
relationship with dose than a broader definition. Even more 
likely than the drug dose is the drug exposure in predicting 
toxicities, as illustrated in the earlier example of high-dose 
paclitaxel and adaptive control. Any attempt to select a valu- 
able measure of exposure in Phase I HDCT trials must also 
be based on existing knowledge about he pharmacology of
the drug and its targets of therapeutic activity and toxicity. 
The ideal study, using pharmacologically guided dose esca- 
lation, takes into account all that is known about he phar- 
macology and ant]neoplastic mechanisms ofthe agent under 
investigation. Technical limitations to this approach include 
the requirement for labor-intensive, real-time pharmacoki- 
netics, the potential for significant drug interactions, the 
fact that some agents have active metabolites, and insuffi- 
cient understanding of the precise drug exposure conditions 
for optimal tumor cell killing. 
A good example of the successful application of statistics 
and pharmacology to Phase I trial design in HDCT studies 
was provided by Stemmer et al. [49]. These investigators 
added paelitaxel at escalating doses to the fixed doses of 
CDDP and CTX from a 3-drug regimen that also contained 
BCNU and was in frequent use in aBMT/aPBSCT for solid 
tumors. The replacement of BCNU with paclitaxel was 
based on the excellent antitumor activity of paclitaxel at 
standard oses and a steep dose-response curve in preclini- 
cal model systems [99,100]. The administration f paclitaxel 
before CDDP was based on pharmacologic data that pre- 
dicted greater eytotoxicity of the paclitaxel --~ CDDP 
sequence and reduction in the pharmacokinetic variability of 
paclitaxel when given prior to CDDP [101]. In their proto- 
col, these investigators prospectively defined dose-related 
toxicities of the 96-hour paclitaxel infusion as distinguished 
Table 4. Guidelines for the Rational Design of Phase I High-Dose 
Chemotherapy Trials* 
I. Preclinical and clinical data supporting selection of the agent to be 
escalated: 
9 Select agents with steep dose-response characteristics in the 
tumor(s) of interest. 
9 Dose-limiting toxicity should be predominantly myelosuppresslon. 
2. Pharmacologic basis for the drug dose and schedule and combina- 
tion with the other components of the regimen: 
9 Existing data provide rationale for the route and schedule. 
9 Antitumor effects are synergistic or additive with the other 
agents in the regimen and have minimal overlapping toxicities. 
9 Assays are available to test pharmacologic end points in the 
dose escalation. 
3. Toxicity grading scale, definition of DLT for estimation of the 
MTD/Phase II dose and schedule, and assessment of late toxicities: 
9 Select a scale that is validated and use it to precisely define the 
parameters for dose escalation and determination of the DLTs. 
9 Distinguish modality-related adverse effects from dose- or 
exposure-related toxicities in determining DLTs. 
9 Provide special considerations for tandem cycles of identical or 
nonidentical regimens. 
9 Assess late-occurring adverse effects (eg, secondary leukemia), 
persistent toxicities (eg, neuropathy, pulmonary fibrosis). 
4. Statistical design and considerations: 
9 Select a statistical design for dose levels and escalation proce- 
dures that will characterize the dose-toxicity relationship and 
include pharmacologic analyses. 
9 Apply the statistical plan throughout the study, avoiding 
exploratory or hypothesis-generating late analyses. 
*DLT indicates dose-limiting toxicity; MTD, ma~mm tolerated dose. 
from regimen-related toxicities. Most importantly, the pro- 
tocol included pharmacokinetic analyses that allowed the 
investigators to evaluate the variability between dose and 
AUC and to demonstrate hat the best predictor of dose- 
limiting peripheral neuropathy and mucositis was the AUC. 
Mthough it is not feasible to test directly the relation- 
ships among dose, AUC or other measures of exposure, tox- 
icity, and antitumor effect in Phase I clinical trials, it is 
essential to recognize the differences between Phase I trials 
of HDCT entities and those of new anfitumor entities, the 
most important of these being the likelihood of therapeutic 
benefit. In Phase I HDCT studies, the clinical and pharma- 
cologic questions are built onto an existing therapeutically 
active regimen, which is believed to be the most appropriate 
therapy for the patient enrolled in the trial. Thus, although 
the selective nature of HDCT investigations poses a major 
challenge to enrolling sufficient patients to answer the 
research questions, the reluctance of third-party payers to 
support pure research studies with little to no therapeutic 
benefit should not play a role. 
CONCLUSIONS 
In this review, we have attempted to summarize the 
published literature reporting Phase I trials of HDCT with 
hematopoietic precursor support and to use the extensive 
contributions of investigators in this challenging field as a 
basis for the development of guidelines for further Phase I
HDCT trials. Important aspects of the published trials were 
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selected for scrutiny to illustrate the obstacles in this field 
and to establish the principles that we recommend be incor- 
porated into new trial design, which are listed in Table 4. 
We recognize that these guidelines do not provide a 
precise formula for all HDCT protocols because the large 
number of variables that need to be addressed in trial 
design demands a customized approach to each study. 
However, we believe that these guidelines do provide inves- 
tigators with the essential elements that need to be consid- 
ered in meeting the challenge of rational clinical trial 
design in HDCT studies. 
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